Anti-Viral Therapy in Alzheimer's Disease

Brief description of study

This study is being conducted to evaluate if the generic anti-viral medication, valacyclovir, is helpful in treating Alzheimer’s disease in patients who have tested positive for antibodies to herpes simplex virus-1 or herpes simplex virus-2 in their blood serum. This study will examine the effects of valacyclovir or placebo on everyday cognition (learning, memory, attention, language, and related mental abilities) and function over an 18-month period.


Clinical Study Identifier: s18-01151
ClinicalTrials.gov Identifier: NCT03282916
Principal Investigator: Thomas M Wisniewski.
Other Investigator: Arjun V. Masurkar.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.